Rahul G Argula1, Charlie Strange2, Viswanathan Ramakrishnan3, Jonathan Goldin4. 1. Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. Electronic address: argula@musc.edu. 2. Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. 3. Division of Epidemiology and Biostatistics, Medical University of South Carolina, Charleston, SC. 4. Department of Radiology, University of California, Los Angeles, CA.
Abstract
BACKGROUND:Advanced heterogeneous emphysema with hyperinflation impacts exercise tolerance in COPD. Bronchoscopic lung volume reduction using Zephyr endobronchial valves (EBVs) has been shown to improve lung function in patients with heterogeneous emphysema. It is unclear whether the target lobe perfusion of patients receiving EBV therapy impacts exercise tolerance as measured by the 6-min walk test distance (6MWTD). METHODS: We performed a retrospective analysis on the treatment group of the Endobronchial Valve for Emphysema Palliation Trial (VENT) to evaluate the impact of perfusion, measured by 99mTc-MAA-perfusion scintigraphy, on the 6-month improvement in 6MWTD. A mixed-model analysis was performed for the treatment outcome, adjusting for other variables such as age, target lobe position, fissure integrity, BMI, sex, destruction score, and lobar exclusion. RESULTS: Dichotomized at the median, of the 169 patients who received EBV therapy, 88 had a low targetlobe regional perfusion and 81 had high target lobe regional perfusion at baseline. Patients with a low targetlobe regional perfusion had a significant improvement in 6MWTD when compared with those with a high baseline target lobe regional perfusion (30.24 m vs 3.72 m, P = .03). Shifts in perfusion after EBV therapy occurred only in patients with high baseline perfusion and did not correlate with improved 6MWTD. CONCLUSIONS:Patients having heterogeneous emphysema with a low baseline target lobe regional perfusion benefit from EBV therapy, independent of the degree of target lobe destruction. This effect is attenuated if the EBV therapy is not occlusive. Characterization of baseline perfusion may enhance clinical results of patients with emphysema undergoing EBV therapy. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00000606; URL: www.clincialtrials.gov.
RCT Entities:
BACKGROUND: Advanced heterogeneous emphysema with hyperinflation impacts exercise tolerance in COPD. Bronchoscopic lung volume reduction using Zephyr endobronchial valves (EBVs) has been shown to improve lung function in patients with heterogeneous emphysema. It is unclear whether the target lobe perfusion of patients receiving EBV therapy impacts exercise tolerance as measured by the 6-min walk test distance (6MWTD). METHODS: We performed a retrospective analysis on the treatment group of the Endobronchial Valve for Emphysema Palliation Trial (VENT) to evaluate the impact of perfusion, measured by 99mTc-MAA-perfusion scintigraphy, on the 6-month improvement in 6MWTD. A mixed-model analysis was performed for the treatment outcome, adjusting for other variables such as age, target lobe position, fissure integrity, BMI, sex, destruction score, and lobar exclusion. RESULTS: Dichotomized at the median, of the 169 patients who received EBV therapy, 88 had a low target lobe regional perfusion and 81 had high target lobe regional perfusion at baseline. Patients with a low target lobe regional perfusion had a significant improvement in 6MWTD when compared with those with a high baseline target lobe regional perfusion (30.24 m vs 3.72 m, P = .03). Shifts in perfusion after EBV therapy occurred only in patients with high baseline perfusion and did not correlate with improved 6MWTD. CONCLUSIONS:Patients having heterogeneous emphysema with a low baseline target lobe regional perfusion benefit from EBV therapy, independent of the degree of target lobe destruction. This effect is attenuated if the EBV therapy is not occlusive. Characterization of baseline perfusion may enhance clinical results of patients with emphysema undergoing EBV therapy. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00000606; URL: www.clincialtrials.gov.
Authors: Hester A Gietema; Kim H M Walraven; Rein Posthuma; Cristina Mitea; Dirk-Jan Slebos; Lowie E G W Vanfleteren Journal: Respiration Date: 2021-08-10 Impact factor: 3.580
Authors: Carmen Pizarro; Robert Schueler; Christoph Hammerstingl; Izabela Tuleta; Georg Nickenig; Dirk Skowasch Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240